01:02:24 Europe / Stockholm
Svenska | English

Mentice

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-07 Kvartalsrapport 2024-Q3
2024-07-23 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning MNTC 0.00 SEK
2024-05-23 Årsstämma 2024
2024-05-03 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-20 Kvartalsrapport 2023-Q2
2023-05-12 Ordinarie utdelning MNTC 0.00 SEK
2023-05-11 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-03 Bokslutskommuniké 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-28 Ordinarie utdelning MNTC 0.00 SEK
2022-04-27 Årsstämma 2022
2022-02-03 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-07-22 Kvartalsrapport 2021-Q2
2021-05-07 Ordinarie utdelning MNTC 0.00 SEK
2021-05-06 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-04 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-13 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning MNTC 0.00 SEK
2020-05-27 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-25 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-08-28 Extra Bolagsstämma 2019

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Mentice är verksamt inom medicinteknik. Bolaget utvecklar medicinska instrument för endovaskulär simulering samt för träningstillfällen inom kirurgi. Programmen är utvecklade för att användas i utbildningssyfte bland sjukhus och institut. Störst verksamhet återfinns inom Nordamerika och Europa. Utöver huvudverksamheten erbjuds möjligheter till leasing, support, samt teknisk service. Huvudkontoret ligger i Göteborg.
Mentice publishes the company’s interim report for the period April – June 2023
2023-07-20 08:30:00

Continued strong performance during the second quarter

Significant events during the quarter

  • Mentice has received a significant repeat order for simulation solutions of approximately 2.4 MUSD, corresponding to approximately 26.0 MSEK from a leading global medical technology company in the USA.
  • Siemens Healthineers and Mentice announced that the collaboration in China, previously focused on Siemens Robotics (Corindus), has been transitioned and enhanced to a general collaboration around innovation and education for the Chinese market.
  • Mentice´s CFO, Gunilla Andersson, resigned at her own request for new challenges outside the company. During the month of June, Mentice appointed Henrik Hang as interim CFO. Henrik has been in the company since mid-June and will formally take over the CFO position as interim CFO on July 21st. Gunilla will remain in the company as support up to her last day in mid-august.


SECOND QUARTER (APRIL– JUNE 2022)

  • Order intake amounted to 77.4 (57.3) MSEK, an increase of 35.1%.
  • Order book by the end of the period was 125.3 (108.9) MSEK, whereof 54.2 MSEK is expected as revenue in 2023.
  • Net sales amounted to 74.3 (45.1) MSEK, an increase of 64.7 %, whereof 54.1% is organic.
  • Earnings before interest, tax, depreciation, and amortization (EBITDA) totaled 10.7 (-12.2) MSEK.
  • Net income for the period amounted to 1.5 (-17.6) MSEK.
  • Earnings per share (EPS) were 0.06 (-0.71) SEK.
  • Cash flow from operating activities totaled 5.2 (-18.3) MSEK.


FIRST HALF YEAR (JANUARY – JUNE 2022)

  • Order intake amounted to 135.1 (111.7) MSEK, an increase of 20.9%.
  • Order book by the end of the period was 125.3 (108.9) MSEK, whereof 54.2 MSEK is expected as revenue in 2023.
  • Net sales amounted to 139.3 (98.2) MSEK, an increase of 41.8 %, whereof 33.6 % is organic.
  • Earnings before interest, tax, depreciation, and amortization (EBITDA) totaled 17.9 (-13.5) MSEK.
  • Net income for the period amounted to 0.0 (-25.1) MSEK.
  • Earnings per share (EPS) were 0.00 (-1.01) SEK.
  • Cash flow from operating activities totaled 2.5 (-7.0) MSEK.


Webcast presentation of the interim report
To register for the presentation, please visit https://investor.mentice.com/

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: goran.malmberg@mentice.com
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22

About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB

This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-07-20 08:30 CEST.

Attachments
Q2 Report EN 23 Final

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden